Shandong Xinhua Pharmaceutical Company Limited 的收入按细分市场或地理位置如何划分?
Shandong Xinhua Pharmaceutical Company Limited 最大收入來源為 Preparation,在最近的收益報告中收入為 4,072,208,527。就地區而言,China (including Hong Kong) 是 Shandong Xinhua Pharmaceutical Company Limited 的主要市場,收入為 6,332,209,258。
Shandong Xinhua Pharmaceutical Company Limited 是否盈利?
是的,根据最新的财务报表,Shandong Xinhua Pharmaceutical Company Limited 的净利潤为 $470
Shandong Xinhua Pharmaceutical Company Limited 有负债吗?
是的,Shandong Xinhua Pharmaceutical Company Limited 的负债为 4,028
Shandong Xinhua Pharmaceutical Company Limited 的流通股有多少?
Shandong Xinhua Pharmaceutical Company Limited 的总流通股为 682.4
關鍵數據
前收市價
$18.19
開盤價
$18.19
當日範圍
$18.19 - $18.19
52週區間
$18.19 - $18.19
交易量
100
平均成交量
0
股息收益率
--
每股盈餘 (TTM)
0.80
市值
$899.9M
什麼是 SHANDONG XINHUA PHARMACEUTICAL ?
Shandong Xinhua Pharmaceutical Co Ltd is a CN-based company operating in Pharmaceuticals industry. The company is headquartered in Zibo, Shandong and currently employs 7,296 full-time employees. Shandong Xinhua Pharmaceutical Co Ltd is a China-based company mainly engaged in the development, manufacturing and sales of chemical raw materials, pharmaceutical preparations and chemical products. The firm operates three segments. The Chemical Raw Materials segment is mainly engaged in the development, manufacturing and sales of raw materials for antipyretics and analgesics such as caffeine series, ibuprofen series, aspirin series, dopamine series, barbiturates and pipemidic acid. The Pharmaceutical Preparations segment is mainly engaged in the development, manufacturing and sales of tablets, injections and capsules such as pipemidic acid tablets, aminopyrine and nimodipine tablets. The Pharmaceutical Intermediates and Other Products segment is mainly engaged in the development, manufacturing and sales of pharmaceutical intermediates and other products. The firm mainly operates its business in the domestic market and overseas markets such as the Americas and Europe.